
Sign up to save your podcasts
Or


On “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, met with Afaf Osman, MD, an Assistant Professor at the University of Utah Huntsman Cancer Center, to discuss how high-risk myelodysplastic syndromes (MDS) are distinct from lower-risk classifications and how to approach treatment.
By Rahul Banerjee, MD4.8
2727 ratings
On “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, met with Afaf Osman, MD, an Assistant Professor at the University of Utah Huntsman Cancer Center, to discuss how high-risk myelodysplastic syndromes (MDS) are distinct from lower-risk classifications and how to approach treatment.

138 Listeners

324 Listeners

498 Listeners

76 Listeners

120 Listeners

28 Listeners

1,145 Listeners

187 Listeners

22 Listeners

369 Listeners

52 Listeners

138 Listeners

48 Listeners

193 Listeners

29 Listeners